Immutep Ltd (IMMP)

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerability in...

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP PR Newswire LOS ANGELES, June 3...

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact...

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

SYDNEY, AUSTRALIA, May 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or...

Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt PR...

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Immutep Receives Nasdaq Notice of Bid Price Deficiency

SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or...

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or...

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or...

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated...

TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis...

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378...

Immutep Quarterly Activities Report Q2 FY26

Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa...